---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038927"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:51:39.350658+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera reports Q2 net loss $34.7M, revenue up 134% YoY; starts Phase 1 for VMS drug ABCL635

## Summary
- Revenue $17.1M vs $7.3M YoY (134% increase); net loss $34.7M ($0.12 loss per share) vs $36.9M ($0.13) prior year.
- First participants dosed in Phase 1 trial of ABCL635 for vasomotor symptoms; initial data expected mid-2026.
- Cumulative partner-initiated program starts reached 102 (+9 YoY); molecules in clinic 18 (+4 YoY).
- Net loss per share $(0.12) versus $(0.13); R&D expenses $39.2M, G&A $19.0M.
- Total liquidity of $753M including $580M cash/securities and $173M in non-dilutive government funding.

## SEC filing metadata
- accession: 0001628280-25-038927
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025038927/0001628280-25-038927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025038927/abcl-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038927
- JSON: https://secwatch.observer/filing/0001628280-25-038927.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.